logo

Breaking News

Share

Apple Inc. (AAPL) apologized over the hacking of some Chinese accounts in phishing scams, almost a week after it emerged that stolen Apple IDs had been used to swipe customer funds, the Wall Street Journal reported. Apple reportedly said it found "a small number of our users' accounts" had been accessed...

Allergan plc (AGN) and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, said that the U.S. Food and Drug Administration approved Medicines360's Supplemental New Drug Application or sNDA to extend the duration of use of LILETTA...

Uber Technologies Inc. recently received proposals from Wall Street banks valuing the ride-hailing company at as much as $120 billion in an initial public offering, the Wall Street Journal reported Tuesday, citing people familiar with the matter. According to the WJS report, the initial public offering...

Prologis, Inc. (PLD) said that it now expects Core funds from operation for fiscal year 2018 to be in the range of $3.01 to $3.03 per share, compared to the prior year outlook of $3.00 to $3.04 per share. The company now projects net earnings per share for 2018 to be in the range of $2.68 to $2.72...

Marvell Technology Group Ltd. (MRVL), a provider of infrastructure semiconductor solutions, said Tuesday that its Board of Directors has authorized a $700 million addition to the balance of its existing share repurchase program. This will increase the total current repurchase authority to $1 billion. Marvell's...

JD Sports Fashion Plc (JD.L) said Tuesday that its Chief Financial Officer Brian Small will step down from the Board of the company with effect from 31 October 2018, following his decision to retire from this role. The company's Board has been in discussion with Brian for the past few months regarding...

Johnson & Johnson (JNJ) on Tuesday, while reporting financial results for the third quarter, raised its adjusted earnings and sales forecast for fiscal 2018. The company raised full-year outlook for adjusted earnings to a range of $8.13 to $8.18 per share. This reflects an increase in expected operational...

Walmart Inc. (WMT) reiterated fiscal 2019 total sales growth expectations and updated GAAP and adjusted EPS to include the expected 25 cents per share Flipkart dilution. Fiscal 2019 adjusted EPS guidance is now $4.65 to $4.80. This is compared to previous guidance for adjusted EPS of $4.90 to $5.05. For...

AstraZeneca and Merck (MRK) announced the U.S. FDA granted orphan drug designation for LYNPARZA for the treatment of pancreatic cancer. LYNPARZA is currently being investigated as maintenance therapy in patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer whose disease has not progressed...

UnitedHealth Group (UNH) raised its outlook for 2018 net earnings per share to now approach $12.10, from the prior range of $11.80 to $12.05, and adjusted net earnings per share to now approach $12.80, from the prior range of $12.50 to $12.75. UnitedHealth Group's third quarter adjusted net earnings...

Volkswagen AG (VKW.L, VLKAF.PK, VOW.BE) announced Tuesday that the Munich II public prosecutor has concluded regulatory offences proceedings against its luxury brand Audi AG (AUDVF.PK) by issuing administrative order imposing a fine of 800 million euros. AUDI has accepted the fine and, by doing so, admits...

Drax Group plc. (DRX.L), engaged in the electricity generation, announced Tuesday that it has agreed to acquire Scottish Power's portfolio of pumped storage, hydro and gas-fired generation for 702 million pounds in cash from Spanish utility Iberdrola (IBDSF.PK), subject to Drax shareholder approval. The...

British drug major AstraZeneca (AZN.L, AZN) and Merck & Co., Inc., (MRK) announced Tuesday that they were granted orphan drug designation or ODD by the US Food and Drug Administration for Lynparza (olaparib) for the treatment of pancreatic cancer, a rare, life-threatening disease. Lynparza (olaparib)...

Merck (MKGAY.PK) announced the company expects strong growth impetus starting next year. The company also confirmed its expectations for full-year business performance in 2018 as communicated on August 9 as well as the expectation that it will return to sustainable growth in 2019 with respect to net...

Novartis (NVS) said that it will present five-year data from the ongoing extensions of the phase III FUTURE 1 and MEASURE 1 studies for Cosentyx or secukinumab in patients with psoriatic arthritis or PsA and ankylosing spondylitis or AS respectively. These new data will be presented at the 2018 American...

Follow RTT